Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant plus palbociclib in ER+/HER2- advanced breast cancer
NCT05909397Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Countries
- 10
01
Overview
A Phase 3 trial of vepdegestrant in estrogen receptor-positive breast cancer (ER+), sponsored by Pfizer. Started Aug 2023; status: active, not recruiting.
02
Drugs
vepdegestrant
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT05909397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909397.